Aging
Conditions
Keywords
Aging, Cell senescence
Brief summary
This study aims to assess the safety and efficacy of study drugs and supplements on clinical (structural and functional) signs of aging and to explore/identify other possible biological measures of aging.
Interventions
DRUGStudy Drugs and Nutritional Supplements
Step 1: 500 mg of metformin and increase their dose 500 mg every 2 weeks up to 2000 mg or until tolerable. Step 2: Once at tolerable daily metformin dose, subjects will take 140 mg of dasatinib along with 58 mg to 174 mg (based on body weight) bio-quercetin and 44.5 mg bio-fisetin. Subjects will take dasatinib, bio-quercetin and bio-fisetin for 2 consecutive days as described 4 times over one year (every 3 months) while participating on this study. Step 3: Two weeks after the first dasatinib dose is complete, subjects will start taking daily nutritional supplements of 1,500 mg glucosamine, 600 mg nicotinamide riboside and 500 mg trans-resveratrol. Step 4: Two weeks after starting daily supplements in Step 3, subjects will take a once weekly 6 mg dose of rapamycin. Once subject is taking rapamycin, they will continue on this intervention for 12 months.
Sponsors
Vitality in Aging Research Group, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Male or female subjects 65 years of age or older 2. Received full dose of COVID-19 vaccine 3. Fasting Glucose: \> 60 - \< 125 mg/dl; 4. HbA1C: \</= 6.4 5. Vitamin D: \> 30 ng/mL 6. Homocysteine \< 14 mol/L 7. B12 levels \>232 pg/mL 8. Ferritin: \> 30 ng/mL 9. Cystatin C: \> 0.62 mg/L 10. eGFR \> 45 mL/min/1.73 m2 11. BMI \> 18 kg/m2 \< 35 kg/m² 12. Stable body weight (+/-10 lbs.) over last 6 months 13. Be willing to travel to the study facility as required for this study 14. Be willing to avoid taking antacids 2 hours prior and 2 hours after taking dasatinib 15. Be willing to discontinue proton pump inhibitors 16. Be willing to discontinue St. John's Wort 17. Be willing to discontinue medication/supplements, if applicable, for a washout period and while participating on this study. 18. If taking metformin for anti-aging, willing to washout for 2 months prior to initiating protocol intervention. 19. Be willing to take the investigational product(s) according to schedule and keep a diary for compliance monitoring. 20. Has not participated in another clinical trial within last 30 days 21. If applicable, five years or more post cancer treatment and disease free (define as tumor free or 5 years of clean PET/CT scans). 22. Able to provide signed written informed consent prior to any study specific procedures being performed.
Exclusion criteria
1. Inability to provide written informed consent. 2. ECOG score \>/= 2 3. More than 1 alcoholic drinks consumed per day. 4. Anemic (defined as hemoglobin (Hb) levels \< 12.0 g/dL in women and \< 13.0 g/dL in men) 5. Thrombocytopenia (defined as platelet count \< 100 × 10\^9/L 6. Neutropenia (defined as \< 1.0-1.5 × 10\^9 neutrophils/L (mild)) 7. Any allergy to any medications or supplements used on this trial. 8. Shellfish or iodine allergy (note: glucosamine sulfate supplement contains shellfish (shrimp, crab) 9. Clinically significant vital signs (e.g. uncontrolled hypertension \>/= 180/100) or lab abnormalities (defined as platelet count \< 100 × 10\^9/L; absolute granulocyte count \< 1,000/mm3; ALT (SGOT) \> 2.0 times the upper limit of normal range; total bilirubin \> 2.5 times the upper limit of normal range) at baseline 10. HIV and/or Hepatitis infection 11. Immunosuppressed due to any condition (e.g. transplant). 12. Taking concurrent medications that may interfere with the drugs or supplements used on this study. 13. Any concurrent uncontrolled medical condition or psychiatric illness which could place the patient at unacceptable risk of study treatment. 14. Other concerns that in the PI's judgment will be a potential safety issue for the subject or that precludes the ability to provide informed consent or complete the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of treatment-emergent adverse events as assessed by CTCAE v5.0 | through study completion, up to post treatment phone (approx. Day 532) | — |
| Visceral adipose tissue fat tissue (volume (in^3)) physiological parameter value measured by DEXA scan | Change from baseline to Visit 20 (approx. Day 502) | — |
| Systolic blood pressure physiological parameter value measured with a blood pressure cuff | Change from baseline to Visit 20 (approx. Day 502) | — |
| Senescent cell-cycle arrest physiological parameter value measured by MMP-9 laboratory test | Change from baseline to Visit 20 (approx. Day 502) | — |
| Glucose control (insulin resistance) physiological parameter as measured by HOMA-IR (mg/dL) calculation value | Change from baseline to Visit 20 (approx. Day 502) | insulin and glucose laboratory values are collected to computer the measurement used |
| DNA Methylation physiological parameter as measured by 2019 GrimAge Clock laboratory test | Change from baseline to Visit 20 (approx. Day 502) | — |
Outcome results
None listed